Newest Indication for Bempedoic Acid Expands Patient Population

In March 2024, the label for bempedoic acid was expanded to reduce cardiovascular risk and expand the low-density lipoprotein-C (LDL-C) lowering in both primary and secondary prevention patients.

Related Keywords

Oregon ,United States , ,Knight Cardiovascular Institute At Oregon Health ,Science University ,American College Of Cardiology ,Pharmacy Times ,Bruce Warden ,Knight Cardiovascular Institute ,Oregon Health ,Esperion Therapeutics ,American College ,